These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 33356392

  • 1. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 2. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
    Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1644-1655. PubMed ID: 29880491
    [Abstract] [Full Text] [Related]

  • 3. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects.
    Taskinen MR, Björnson E, Andersson L, Kahri J, Porthan K, Matikainen N, Söderlund S, Pietiläinen K, Hakkarainen A, Lundbom N, Nilsson R, Ståhlman M, Adiels M, Parini P, Packard C, Borén J.
    J Clin Lipidol; 2020 Jul; 14(1):77-87. PubMed ID: 31917184
    [Abstract] [Full Text] [Related]

  • 4. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 5. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.
    Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Hakkarainen A, Lundbom N, Lundbom J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Borén J.
    J Intern Med; 2020 Oct; 288(4):422-438. PubMed ID: 31846520
    [Abstract] [Full Text] [Related]

  • 6. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS.
    Cardiovasc Diabetol; 2021 Apr 30; 20(1):94. PubMed ID: 33941192
    [Abstract] [Full Text] [Related]

  • 7. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.
    Taskinen MR, Matikainen N, Björnson E, Söderlund S, Inkeri J, Hakkarainen A, Parviainen H, Sihlbom C, Thorsell A, Andersson L, Adiels M, Packard CJ, Borén J.
    Diabetologia; 2023 Dec 30; 66(12):2307-2319. PubMed ID: 37775612
    [Abstract] [Full Text] [Related]

  • 8. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jul 10; 138(2):131-140. PubMed ID: 29530884
    [Abstract] [Full Text] [Related]

  • 9. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jan 23; 137(4):338-350. PubMed ID: 29133605
    [Abstract] [Full Text] [Related]

  • 10. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM.
    Taskinen MR, Packard CJ, Shepherd J.
    Diabetes; 1990 Sep 23; 39(9):1017-27. PubMed ID: 2200727
    [Abstract] [Full Text] [Related]

  • 11. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
    Vergès B, Duvillard L, Pais de Barros JP, Bouillet B, Baillot-Rudoni S, Rouland A, Petit JM, Degrace P, Demizieux L.
    Diabetes Care; 2021 Apr 23; 44(4):1027-1037. PubMed ID: 33531418
    [Abstract] [Full Text] [Related]

  • 12. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.
    Taskinen MR, Björnson E, Matikainen N, Söderlund S, Rämö J, Ainola MM, Hakkarainen A, Sihlbom C, Thorsell A, Andersson L, Bergh PO, Henricsson M, Romeo S, Adiels M, Ripatti S, Laakso M, Packard CJ, Borén J.
    JCI Insight; 2022 Oct 10; 7(19):. PubMed ID: 36040803
    [Abstract] [Full Text] [Related]

  • 13. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.
    Cardiovasc Diabetol; 2019 Nov 09; 18(1):149. PubMed ID: 31706300
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, Letierce A, Thompson D, Colhoun HM.
    Atherosclerosis; 2018 Sep 09; 276():124-130. PubMed ID: 30059843
    [Abstract] [Full Text] [Related]

  • 15. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
    Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, McCormick SP, Marcovina SM, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2015 Dec 09; 35(12):2686-93. PubMed ID: 26515419
    [Abstract] [Full Text] [Related]

  • 16. Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.
    Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Borén J.
    J Intern Med; 2019 May 09; 285(5):562-577. PubMed ID: 30779243
    [Abstract] [Full Text] [Related]

  • 17. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism?
    Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH.
    Metabolism; 2000 Aug 09; 49(8):1049-54. PubMed ID: 10954025
    [Abstract] [Full Text] [Related]

  • 18. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
    Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M.
    J Am Heart Assoc; 2020 Mar 03; 9(5):e014129. PubMed ID: 32114889
    [Abstract] [Full Text] [Related]

  • 19. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N.
    Eur J Prev Cardiol; 2018 Nov 03; 25(17):1843-1851. PubMed ID: 30058841
    [Abstract] [Full Text] [Related]

  • 20. Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes.
    Li T, Zhang Y, Cong H.
    BMC Cardiovasc Disord; 2021 Jan 07; 21(1):19. PubMed ID: 33413096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.